– Reuters
European Medicines Agency Accepted Marketing Authorization Application For Lecanemab As Treatment For Early Alzheimer’s Disease
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab (Brand Name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril antibody[1], for the treatment of Early Alzheimer's disease (mild cognitive impairment due to Alzheimer's disease (AD)
